[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercholesterolemia-familial\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercholesterolemia-familial":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,79,106],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100634749","a-real-world-study-of-long-term-adherence-and-persistence-to-inclisiran-evolocumab-and-alirocumab-100634749",false,"NCT07543731","A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab","Real-World Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab in Italy","VICTORION-LEAP","Inclusion criteria:\n\n* A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.\n* Age ≥18 years at index date.\n* With at least 12 months data availability prior to index date.\n\nExclusion criteria:\n\n• Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.","ALL","18 Years","99 Years",{"count":21,"type":22},5995,"ESTIMATED","OBSERVATIONAL","This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin\u002Fkexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical practice.",[26,27,28],"Cardiovascular Diseases","Atherosclerotic Cardiovascular Disease","Hypercholesterolemia, Familial",[30,31,32,33,34,35],"Real-world","Retrospective","Adherence","Persistence","Long-term","PCSK9i","NOT_YET_RECRUITING","2026-04-14",{"date":39,"type":40},"2026-04-22","ACTUAL",{"date":42,"type":22},"2026-04-21",{"date":44,"type":22},"2026-09-30",{"name":46,"class":47},"Novartis Pharmaceuticals","INDUSTRY",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":78},"100558745","screening-for-familial-hypercholesterolemia-in-children-100558745","NCT06555120","Screening for Familial Hypercholesterolemia in Children","HYPERCHOF","Inclusion Criteria:\n\n* Age between 2 and 18 years\n* Minimum 8-hour fasting\n* Parents and children with signed informed consent\n\nExclusion Criteria:\n\n* Known familial hypercholesterolemia\n* Diabetes less than one month old\n* Profound hypothyroidism\n* Acute nephrotic syndrome\n* cancer under treatment",true,"2 Years",{"count":58,"type":22},300,"INTERVENTIONAL",[61],"NA","Familial hypercholesterolemia is the most common treatable genetic disorder for which a simple, effective treatment is available, with few side effects.\n\nIt leads to a significant increase in LDL levels, generally in excess of 1.9g\u002Fl, including in children. It is much higher than the values usually found in secondary or polygenic hypercholesterolemia. This condition multiplies the cardiovascular risk in adulthood by a factor of 13, and is responsible for 6,500 early cardiovascular events per year. In the absence of treatment, the state of the arteries of patients with familial hypercholesterolemia, at the age of 40, would be equivalent to that of 80-year-olds.\n\nCurrently, the prevalence is estimated at 1 in 300 people in France. However, this prevalence is largely underestimated, as targeted screening is rarely carried out, and it is estimated that only 10% of sufferers are diagnosed in France, and only 5% of affected children are known and treated.\n\nToday, according to the French health authority, the indications for screening children are: a history of an early vascular event in one of the two parents, or familial hypercholesterolemia in a first-degree relative.\n\nHowever, the World Health Organization and numerous studies recommend extending screening to the general population. Screening all children and teenagers could make it possible to introduce healthy dietary habits at an early stage, to better adapt the choice of contraception in young women, to treat before the first symptoms appear and thus reduce mortality in adulthood by up to 48%, and to screen relatives who have not yet had a cardiovascular event.\n\nIn Slovenia, 90% of children have had a lipid panel since 1994, significantly reducing mortality. In the United Kingdom, the lipid check-up, offered as part of a compulsory visit at the age of two, is being rolled out: 90% of families naturally take it up on the recommendation of their doctors.\n\nThe treatment of hypercholesterolemia is simple, and relies first and foremost on hygienic dietary rules and treatments such as statins and Liptruzet (a combination of atorvastatin and ezetimibe), treatments that are easily accessible, effective, with few side effects and low cost.",[28],[65,66],"hypercholesterolemia","familial","RECRUITING","2026-02-10",{"date":70,"type":40},"2026-02-12",{"date":72,"type":40},"2025-01-02",{"date":74,"type":22},"2027-02",{"name":76,"class":77},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":59,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":78},"100361670","clinical-decision-support-for-familial-hypercholesterolemia-100361670","NCT03989167","Clinical Decision Support for Familial Hypercholesterolemia","Clinical Decision Support for Familial Hypercholesterolemia: a Cluster Randomized Trial in the Primary Care Setting","CDS-FH","Inclusion Criteria\n\n* Primary care centers in the county of Östergötland.\n\nExclusion Criteria\n\n* Primary care centers not using the Cambio Cosmic Electronic Health Record System.","80 Years",{"count":89,"type":22},460000,[61],"A cluster randomized study in the primary care setting to evaluate a computer-based clinical decision support system to aid in the identification and management of patients with FH. The primary outcome of the study is the number of patients diagnosed with FH thirty-six months after study initiation.",[28,93],"Clinical Decision Support",[28,95,96],"Primary care","Clinical decision support","2024-11-22",{"date":99,"type":40},"2024-11-26",{"date":101,"type":40},"2022-12-06",{"date":103,"type":22},"2025-12-06",{"name":105,"class":77},"University Hospital, Linkoeping",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":113,"targetDuration":4,"studyType":59,"phases":115,"briefSummary":116,"conditions":117,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":78},"100368168","pet-imaging-of-inflammation-and-lipid-lowering-study-100368168","NCT04073797","PET Imaging of Inflammation and Lipid Lowering Study","PIILL","Inclusion Criteria:\n\n* Male or female participants \\>18 years old\n* Able to give written, informed consent and to lie flat\n* Have primary hypercholesterolaemia (non-familial or definite or possible heterozygous familial hypercholesterolaemia (HeFH) based on clinical criteria) or mixed dyslipidaemia, and\n* History of CVD (acute coronary syndrome, coronary or other revascularisation procedures, coronary heart disease, ischaemic stroke, or peripheral arterial disease) and elevated LDL cholesterol ≥2.6 despite maximum tolerated statins with or without other lipid lowering therapies (see NICE TA 733), and\n* Lipid lowering therapy unchanged for at least 6 weeks prior to screening, and\n* Pre-existing carotid atherosclerotic plaque ≥15mm by B-mode ultrasound\n\nExclusion Criteria:\n\n* Women of childbearing potential not using adequate contraception\n* Contra-indication to MRI scanning\n* Statin-associated myositis or liver function abnormality\n* Already taking inclisiran or colchicine\n* Sensitivity and\u002For contraindication to inclisiran or colchicine. Contraindications to colchicine include severe hepatic or renal impairment, blood disorders, and patients with renal or hepatic impairment who are taking a P-gp inhibitor or a strong CYP3A4 inhibitor\n* Contrast allergy or contrast-nephropathy\n* Chronic kidney disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2)\n* Cardiovascular event within 6 months\n* Any medical condition, in the opinion of the investigator, that prevents the participant from lying flat during scanning, or from participating in the study\n* Uncontrolled chronic inflammatory disorder\n* History of recent malignancy deemed relevant to the study by the investigator\n* Treatment with medications that result in significant drug to drug interactions with the study medications\n* Current use of systemic corticosteroids or other immunosuppressive drugs\n* Previous or planned carotid endarterectomy surgery or stenting on the index side",{"count":114,"type":22},63,[61],"While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has been used as an early marker of drug efficacy in numerous clinical cardiovascular drug trials, as a glucose analog, its signal in the vasculature lacks inflammatory cell-specificity. Moreover, high background 18F-FDG signals from the myocardium often preclude coronary artery imaging, despite attempts to suppress myocardial tracer uptake by dietary manipulation. These limitations of 18F-FDG for measuring changes in vascular inflammation arising from drug intervention highlight important unmet needs, which might be overcome by using a somatostatin receptor subtype-2 (SST2) PET tracer.",[118,28,119,120],"Hypercholesterolemia","Atherosclerosis","Carotid Artery Plaque","2024-07-18",{"date":123,"type":40},"2024-07-19",{"date":125,"type":40},"2023-03-20",{"date":127,"type":22},"2026-03-01",{"name":129,"class":77},"University of Cambridge"]